Unexpected drug interactions and adverse events with antiretroviral drugs
2004; Elsevier BV; Volume: 364; Issue: 9428 Linguagem: Inglês
10.1016/s0140-6736(04)16608-7
ISSN1474-547X
Autores Tópico(s)HIV-related health complications and treatments
ResumoEsteban Martinez and colleagues, in today's Lancet, report cohort data indicating that the combination of didanosine with tenofovir results in a significantly higher incidence of pancreatitis than regimens containing didanosine or tenofovir alone. Pancreatitis events, as well as hyperlipasaemia and hyperamylasaemia, were seen in patients taking 400 mg or 250 mg didanosine with tenofovir. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adultsThe rise in didanosine concentrations in plasma when given with tenofovir raises concern for a high risk of toxic effects. Recommendations to reduce didanosine dose have been issued, but only for adults weighing more than 60 kg. We reviewed cases of pancreatitis in patients receiving didanosine plus tenofovir, didanosine alone, and tenofovir alone to assess the incidence of and risk factors for pancreatitis. Between Aug 1, 2001, and Nov 30, 2003, five of 185 (2·7%) patients receiving didanosine plus tenofovir, one of 182 (0·5%) on didanosine without tenofovir, and none of 208 on tenofovir without didanosine developed pancreatitis (p=0·016). Full-Text PDF
Referência(s)